Key Decision and Approval

  • The Nomination and Remuneration Committee (NRC) of the Board of Directors approved the grant via resolution passed by circulation on September 3, 2026
  • Approval covers grant of 4,01,362 (Four Lakh One Thousand Three Hundred and Sixty-Two) Employee Stock Options to eligible employees
  • Options granted under the NephroPlus Employee Stock Option Scheme 2026 (ESOP 2026)

Option Details

  • Total Options Granted: 4,01,362
  • Face Value per Share: ₹2
  • Exercise Price per Option: ₹230 (Rupees Two Hundred and Thirty only)
  • Conversion Ratio: Each Option converts to one fully paid-up equity share upon vesting and exercise
  • Total Potential Shares: 4,01,362 equity shares (assuming full vesting and exercise of all Options)

Vesting and Exercise Conditions

  • Minimum Vesting Period: One year from the Grant Date
  • Vesting Conditions: Subject to fulfillment of applicable vesting conditions specified in respective Grant Letters
  • Exercise Period: Vested Options may be exercised within maximum 5 years from each respective vesting date
  • Early Exercise: Possible within shorter period as prescribed by NRC and specified in Grant Letters
  • Cessation Provisions: Exercise period governed by applicable provisions of ESOP 2026 in event of employment/service cessation

Additional Information

  • Information available on company website: www.nephroplus.com
  • Signed by Kishore Kathri, Company Secretary and Head Legal (Membership No.: F9895)
  • Digital signature timestamp: September 3, 2026 at 11:02:15 +05:30

Current Status Indicators

  • Options Vested: Not applicable at this stage
  • Options Exercised: Not applicable at this stage
  • Money Realized: Not applicable at this stage
  • Shares Issued: Not applicable at this stage
  • Options Lapsed: Not applicable at this stage
  • Subsequent Changes: Not applicable at this stage
  • Diluted EPS Impact: Not applicable at this stage

Significant Terms

  • Options governed by ESOP 2026, respective Grant Letters, and SEBI SBEB Regulations
  • Unvested Options automatically lapse if vesting conditions not fulfilled within stipulated period
  • Lapsed Options return to ESOP pool for future grants without requiring further NRC approval